Overall, our findings suggest that cabozantinib plus durvalumab clinical synergy is potentially explained by cabozantinib induced modulation of angiogenesis by VEGF receptor inhibition and ECM modulation possibly through interruption of joint integrin c-MET signaling leading to an improved T-cell migration into the tumor core with synergistic durvalumab promoted effective anti-tumor immune response. This evidence concerns the gene MET and neoplasm.